The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in Alzheimer's disease (AD) in which all proposed treatments investigated in murine models have failed during clinical trials (CTs). Thus, novel therapeutic strategies remain crucial. Neuroinflammation is a common pathogenic feature of NDDs. As purinergic P2X7 receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug targets for NDDs. Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their molecular structure and functions, as well as their role in inflammation. Then, we elaborate on research undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists. Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and retinal degeneration. Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs. Finally, we reviewed previous and ongoing CTs investigating compounds directed toward targets associated with NDDs; we propose that CTs with P2X7R antagonists should be initiated. Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs. A better pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
How neuroinflammation contributes to neurodegeneration
Ransohoff, R. M. (2016) · Science · doi:10.1126/science.aag2590 · Cited by 1,967 · cited 1×
“levels of inflammatory mediators present in the parenchyma of the brain or spinal cord in patients with NNDs; in the long term, this low inflammatory status leads to synaptic dysfunction, loss of synapses, and neuronal death.(142)”
BackgroundBurnstock, G. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06930-3 · Cited by 1,852
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
Surprenant, A., Rassendren, F., Kawashima, E., North, R. A., & Buell, G. (1996) · Science · doi:10.1126/science.272.5262.735 · Cited by 1,739 · cited 10×
“This response was attributed to a specific type of membrane receptors of the purinergic type, initially labeled P2Z,(33) and later identified as P2X7Rs.(34) In the 1990s, P2Z/P2X7 activation was involved in the release of interleukin‐1β (IL‐1β), as well as macrophage communication and differentiation.”
BackgroundInfluentialCost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Neuroinflammation: The Devil Is in the Details
DiSabato, D. J., Quan, N., & Godbout, J. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13607 · Cited by 1,640 · cited 19×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluential-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · cited 1×
“Furthermore, the accumulation of oligomerized α‐synuclein is postulated to mediate neurotoxicity by activating microglia, followed by the production of ROS and proinflammatory mediators.(167) Importantly, α‐synuclein binds to P2X7Rs in microglia and stimulates P2X7R transcription,(168) thus explaining the upregulation…”
BackgroundActivation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445 · cited 2×
“This intracellular K drop is possibly the best‐established mechanism underlying P2X7R‐mediated formation of the NLRP3 inflammasome.(77)”
BackgroundThe P2X7 Receptor in Infection and Inflammation
Di Virgilio, F., Dal Ben, D., Sarti, A. C., Giuliani, A. L., & Falzoni, S. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.020 · Cited by 1,267 · cited 19×
“BBG has been utilized in both in vitro and in vivo experiments; however, this compound also targets P2X4, P2X5, rat P2Y1, and P2Y2 receptors, as well as voltage‐gated sodium channels.8,95,96 BBG was initially the main compound used for the proof‐ of‐concept of P2X7Rs role in NDDs, such as ALS and AD.97–99 Its permeabi…”
BackgroundInfluentialMulti-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Cited by
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
D’Amico, R., Fusco, R., Siracusa, R., Impellizzeri, D., Peritore, A. F., Gugliandolo, E., Interdonato, L., Sforza, A. M., Crupi, R., Cuzzocrea, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126471 · Cited by 51
“This is understandable, considering that P2X7Rs are expressed by immune and inflammatory cells and are upregulated in inflammatory processes, including mast cells, dendritic cells and microglia, the most widely studied cells from the monocyte/macrophage axis [29].”
BackgroundIn Situ Detection of Neuroinflammation Using Multicellular 3D Neurovascular‐Unit‐on‐a‐Chip
Choi, J., Choi, H. K., & Lee, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202304382 · Cited by 21
Metadata
- Authors
- Calzaferri, F., Ruiz‐Ruiz, C., de Diego, A. M. G., de Pascual, R., Méndez‐López, I., Cano‐Abad, M. F., Maneu, V., de los Ríos, C., Gandía, L., & García, A. G.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-07-16
- Volume
- 40
- Issue
- 6
- Pages
- 2427-2465
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3042775141
- Cited by
- 97
- References
- 40
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases. https://app.cochat.ai/papers/10.1002/med.21710
- The paper
- Calzaferri, F., Ruiz‐Ruiz, C., de Diego, A. M. G., de Pascual, R., Méndez‐López, I., Cano‐Abad, M. F., Maneu, V., de los Ríos, C., Gandía, L., & García, A. G. (2020). The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases. Medicinal Research Reviews. https://doi.org/10.1002/med.21710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.